Mirna Goes Nuclear
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Abou Alezz, Monah Characterization of the Genomic and Splicing Features of Long 51 Non-Coding Rnas Using Bioinformatics Approaches
Posters A-Z Abou Alezz, Monah Characterization of the genomic and splicing features of long 51 non-coding RNAs using bioinformatics approaches Aguilera-Cortés, Paulina Identification of cellular lncRNAs associated to the HIV-1 genomic RNA 52 by interactome capture Ahram, Mamoun The androgen, dihydrotestosterone, induces chemoresistance of triple 53 negative breast cancer cells independent of ABCG2 and microRNA-328-3p Ahunbay, Esra Watching the self-catalyzed splicing of a group II intron with 54 single-molecule sensitivity Alemu, Endalkachew Integrated Global Mapping of miRNA:target-RNA Interactions 55 Ali, Tamer The lncRNA locus Handsdown regulates cardiac gene programs and is 56 essential for early mouse development Alzahrani, Salma Revisiting the sRNAome Under a Revised MicroRNA Annotation Criteria 57 Amorim, Marcella Dissecting the threshold-based readout of mobile small RNA gradients 58 Arnoldi, Michele SINEUPs technology: a new route to possibly treat 59 haploinsufficiency-induced Epilepsy and Autism Spectrum Disorders (ASDs) Azhikina, Tatyana Small RNA F6 influences Mycobacterium smegmatis entry into 60 dormancy EMBO | EMBL Symposium: The Non-Coding Genome Barasa, Sheila Olendo Long non-coding RNAs in High Grade Serous Ovarian Carcinoma 61 Behera, Alok LIN28 as a new drug target 62 Behrmann, Iris Modulation of the IL-6-Signaling Pathway in Liver Cells by miRNAs 63 Targeting gp130, JAK1, and/or STAT3 Bencurova, Petra Inhibition of miRNA-129-2-3p increases risk and severity of seizures in 64 developing brain Bica, Cecilia The emerging -
Enhancer Rnas: Transcriptional Regulators and Workmates of Namirnas in Myogenesis
Odame et al. Cell Mol Biol Lett (2021) 26:4 https://doi.org/10.1186/s11658-021-00248-x Cellular & Molecular Biology Letters REVIEW Open Access Enhancer RNAs: transcriptional regulators and workmates of NamiRNAs in myogenesis Emmanuel Odame , Yuan Chen, Shuailong Zheng, Dinghui Dai, Bismark Kyei, Siyuan Zhan, Jiaxue Cao, Jiazhong Guo, Tao Zhong, Linjie Wang, Li Li* and Hongping Zhang* *Correspondence: [email protected]; zhp@sicau. Abstract edu.cn miRNAs are well known to be gene repressors. A newly identifed class of miRNAs Farm Animal Genetic Resources Exploration termed nuclear activating miRNAs (NamiRNAs), transcribed from miRNA loci that and Innovation Key exhibit enhancer features, promote gene expression via binding to the promoter and Laboratory of Sichuan enhancer marker regions of the target genes. Meanwhile, activated enhancers pro- Province, College of Animal Science and Technology, duce endogenous non-coding RNAs (named enhancer RNAs, eRNAs) to activate gene Sichuan Agricultural expression. During chromatin looping, transcribed eRNAs interact with NamiRNAs University, Chengdu 611130, through enhancer-promoter interaction to perform similar functions. Here, we review China the functional diferences and similarities between eRNAs and NamiRNAs in myogen- esis and disease. We also propose models demonstrating their mutual mechanism and function. We conclude that eRNAs are active molecules, transcriptional regulators, and partners of NamiRNAs, rather than mere RNAs produced during enhancer activation. Keywords: Enhancer RNA, NamiRNAs, MicroRNA, Myogenesis, Transcriptional regulator Introduction Te identifcation of lin-4 miRNA in Caenorhabditis elegans in 1993 [1] triggered research to discover and understand small microRNAs’ (miRNAs) mechanisms. Recently, some miRNAs are reported to activate target genes during transcription via base pairing to the 3ʹ or 5ʹ untranslated regions (3ʹ or 5ʹ UTRs), the promoter [2], and the enhancer regions [3]. -
Mirna Activation Is an Endogenous Gene Expression Pathway
RNA Biology ISSN: 1547-6286 (Print) 1555-8584 (Online) Journal homepage: http://www.tandfonline.com/loi/krnb20 miRNA activation is an endogenous gene expression pathway Dr. Luis M. Vaschetto To cite this article: Dr. Luis M. Vaschetto (2018): miRNA activation is an endogenous gene expression pathway, RNA Biology, DOI: 10.1080/15476286.2018.1451722 To link to this article: https://doi.org/10.1080/15476286.2018.1451722 Accepted author version posted online: 14 Mar 2018. Submit your article to this journal View related articles View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=krnb20 Publisher: Taylor & Francis Journal: RNA Biology DOI: https://doi.org/10.1080/15476286.2018.1451722 Title: miRNA activation is an endogenous gene expression pathway Author Dr. Luis M. Vaschetto*1,2 Affiliations 1 Instituto de Diversidad y Ecología Animal, Consejo Nacional de Investigaciones Científicas y Técnicas (IDEA, CONICET), Av. Vélez Sarsfield 299, X5000JJC Córdoba, Argentina. 2 Cátedra de Diversidad Animal I, Facultad de Ciencias Exactas, Físicas y Naturales, Universidad Nacional de Córdoba, (FCEFyN, UNC), Av. Vélez Sarsfield 299, X5000JJC Córdoba, Argentina. Corresponding author’s phone and e-mails Phone: 0054-3572- 445-6144 E-mails: [email protected] (primary e-mail); [email protected] Abstract Transfection of small non-coding RNAs (sncRNAs) molecules has become a routine technique widely used for silencing gene expression by triggering post- transcriptional and transcriptional RNA interference (RNAi) pathways. Moreover, in the past decade, small activating (saRNA) sequences targeting promoter regions were also reported, thereby a RNA-based gene activation (RNAa) mechanism has been proposed. -
RNA Activation flew in the Face of at Dallas, Was Convinced She Had Messed Would Be Even More Unbelievable Than What Everyone’S Perceived Wisdom Regarding Something Up
MODIFIED FROM ORIGINAL PHOTO. © 2009, THE ANN ARBOR NEWS. ALL RIGHTS RESERVED. REPRINTED WITH PERMISSION. fter getting the tion by as much as 90%.1 Interestingly, the other genes could also switch on gene data back from the findings confirmed work by Kevin Morris, mkZgl\kbimbhg'Ebd^<hk^rZg]CZghpldb% very first experi- now at the Scripps Research Institute in EbZg]IeZ\^p^k^^qi^\mbg`bgZ\mboZmbhg% ment at her new EZCheeZ%<Zeb_'%pahaZ]in[ebla^]ma^Öklm ghmma^hiihlbm^'ÊP^p^k^lnkikbl^]maZm job, Rosalyn Ram, evidence of this phenomenon in human we didn’t observe gene silencing by the a lab technician cells a year earlier. ]hn[e^&lmkZg]^]KG:%ËlZrlEb'ÊBglm^Z]% at the University ;nm<hk^rZg]CZghpldbZelhghmb\^] we observed strong gene activation.” of Texas Southwestern Medical Center something in their data that, if correct, RNA activation flew in the face of at Dallas, was convinced she had messed would be even more unbelievable than what everyone’s perceived wisdom regarding something up. The results were decidedly Ram saw on her first day at the bench. A few RNA-based regulation. RNA was thought Êp^bk]%Ëla^k^\Zeel'A^keZ[a^Z]l%ma^ h_<hk^rZg]CZghpldbÍll^^fbg`erÊbgZ\- to silence genes only by cutting up mRNA husband-and-wife research duo David tive” RNAs that did not reduce gene expres- via the RNAi pathway, not at the point <hk^rZg];^maZgrCZghpldb%aZ]Zek^Z]r sion reproducibly enhanced transcription of gene transcription and definitely not shown that synthetic DNA molecules with by around 25% to 50%. -
Small Activating Rnas: Towards the Development of New Therapeutic Agents and Clinical Treatments
cells Review Small Activating RNAs: Towards the Development of New Therapeutic Agents and Clinical Treatments Hossein Ghanbarian 1,2, Shahin Aghamiri 3 , Mohamad Eftekhary 2 , Nicole Wagner 4,*,† and Kay-Dietrich Wagner 4,*,† 1 Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran; [email protected] 2 Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran; [email protected] 3 Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran 19839-63113, Iran; [email protected] 4 Université Côte d’Azur, CNRS, INSERM, iBV, 06107 Nice, France * Correspondence: [email protected] (N.W.); [email protected] (K.-D.W.); Tel.: +33-493-3776-65 (K.-D.W.) † Equal Contribution. Abstract: Small double-strand RNA (dsRNA) molecules can activate endogenous genes via an RNA-based promoter targeting mechanism. RNA activation (RNAa) is an evolutionarily conserved mechanism present in diverse eukaryotic organisms ranging from nematodes to humans. Small acti- vating RNAs (saRNAs) involved in RNAa have been successfully used to activate gene expression in cultured cells, and thereby this emergent technique might allow us to develop various biotechnologi- cal applications, without the need to synthesize hazardous construct systems harboring exogenous Citation: Ghanbarian, H.; Aghamiri, S.; Eftekhary, M.; Wagner, N.; Wagner, DNA sequences. Accordingly, this thematic issue aims to provide insights into how RNAa cellular K.-D. Small Activating RNAs: machinery can be harnessed to activate gene expression leading to a more effective clinical treatment Towards the Development of New of various diseases. -
RNA Activation: a Diamond in the Rough for Genome Engineers†
Letter to the Editor RNA activation: a diamond in the rough for genome engineers† Running title: RNA activation Dr. Luis María Vaschetto*1,2 Affiliations 1 Instituto de Diversidad y Ecología Animal, Consejo Nacional de Investigaciones Científicas y Técnicas (IDEA, CONICET), Av. Vélez Sarsfield 299, X5000JJC Córdoba, Argentina. 2 Cátedra de Diversidad Animal I, Facultad de Ciencias Exactas, Físicas y Naturales, Universidad Nacional de Córdoba, (FCEFyN, UNC), Av. Vélez Sarsfield 299, X5000JJC Córdoba, Argentina. Corresponding author’s phone and e-mails Phone: 0054-3572- 445-6144 E-mails: [email protected] (primary e-mail); [email protected] †This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: [10.1002/jcb.26228] Received 6 May 2017; Revised 18 June 2017; Accepted 20 June 2017 Journal of Cellular Biochemistry This article is protected by copyright. All rights reserved DOI 10.1002/jcb.26228 This article is protected by copyright. All rights reserved Abstract The ability to develop efficient and versatile technologies for manipulating gene expression is a fundamental issue both in biotechnology and therapeutics. The endogenous RNA interference (RNAi) pathway which mediates gene silencing was discovered at the end of the 20th century and it is nowadays considered as an essential strategy for knockdown of specific genes and for studying gene function. Remarkably, during the past decade, a RNA-induced mechanism of gene activation has also been reported. -
Mireya: a Computational Approach to Detect Mirna- Directed Gene Activation [Version 2; Peer Review: 1 Approved, 2 Approved with Reservations]
F1000Research 2021, 10:249 Last updated: 01 SEP 2021 SOFTWARE TOOL ARTICLE MIREyA: a computational approach to detect miRNA- directed gene activation [version 2; peer review: 1 approved, 2 approved with reservations] Anna Elizarova 1,2, Mumin Ozturk3,4, Reto Guler3-5, Yulia A. Medvedeva1,2 1Group of Regulatory Transcriptomics and Epigenomics, Research Center of Biotechnology, Institute of Bioengineering, Russian Academy of Sciences, Moscow, 117312, Russian Federation 2Department of Biological and Medical Physics, Moscow Institute of Physics and Technology (National Research University), Dolgoprudny, 141701, Russian Federation 3International Centre for Genetic Engineering and Biotechnology, Cape Town, Cape Town, 7925, South Africa 4Department of Pathology, University of Cape Town, Institute of Infectious Diseases and Molecular Medicine (IDM), Division of Immunology and South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Faculty of Health Sciences, Cape Town, 7925, South Africa 5Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine (IDM), Faculty of Health Sciences, University of Cape Town, Cape Town, 7925, South Africa v2 First published: 29 Mar 2021, 10:249 Open Peer Review https://doi.org/10.12688/f1000research.28142.1 Latest published: 26 Aug 2021, 10:249 https://doi.org/10.12688/f1000research.28142.2 Reviewer Status Invited Reviewers Abstract Emerging studies demonstrate the ability of microRNAs (miRNAs) to 1 2 3 activate genes via different mechanisms. Specifically, miRNAs may trigger an enhancer promoting chromatin remodelling in the version 2 enhancer region, thus activating the enhancer and its target genes. (revision) report Here we present MIREyA, a pipeline developed to predict such miRNA- 26 Aug 2021 gene-enhancer trios based on an expression dataset which obviates the need to write custom scripts. -
Development of MTL-CEPBA: Sarna Drug for Liver Disease
Send Orders for Reprints to [email protected] Journal Name, Year, Volume 1 Development of MTL-CEPBA: SaRNA drug for Liver Disease Helen L Lightfoot†a, Ryan L Setten†b,c, John J Rossib,c and Nagy A Habibd* aMiNA Therapeutics Limited, Translation & Innovation Hub, 80 Wood Lane, London, W12 0BZ, United Kingdom; bDepartment of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA; cIrell & Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA; dDepartment of Surgery and Cancer, Imperial College London, London, UK. †authors contributed equally Abstract: Oligonucleotide drug development has revolutionised the drug discovery field allowing the notorious “undruggable” genome to become “druggable”. Of course, as with all, there are caveats to this new technology, which include restricted delivery and mode of actions – such drugs usually alter splicing and reduce RNA at the post- transcriptional level. Small activating RNA (saRNA)-mediated gene activation has opened a new potential therapeutic avenue for oligonucleotide drugs. SaRNAs promote endogenous transcription, a phenomenon known as RNA activation (RNAa), hence they function to increase gene expression levels. SaRNA based oligonucleotide therapeutics present great promise in expanding the “druggable” genome, with particular areas of interest including transcription factor activation and haploinsufficency. In this mini-review, we describe the pre-clinical development of the first saRNA drug to enter the clinic. This saRNA, referred to as MTL-CEPBA, targets the transcription factor CCAAT/enhancer-binding protein alpha (CEBPα), a tumour suppressor and critical regulator of hepatocyte function. MTL-CEPBA is presently in Phase I clinical trials for hepatocellularcarcinoma (HCC). -
Nucleoside Modifications Suppress RNA Activation of Cytoplasmic RNA Sensors
University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Fall 2010 Nucleoside Modifications Suppress RNA Activation of Cytoplasmic RNA Sensors Bart R. Anderson University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Molecular Biology Commons Recommended Citation Anderson, Bart R., "Nucleoside Modifications Suppress RNA Activation of Cytoplasmic RNA Sensors" (2010). Publicly Accessible Penn Dissertations. 1567. https://repository.upenn.edu/edissertations/1567 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1567 For more information, please contact [email protected]. Nucleoside Modifications Suppress RNA Activation of Cytoplasmic RNA Sensors Abstract Multiple innate defense pathways exist to recognize and defend against foreign nucleic acids. Unlike innate immune receptors that recognize structures specific for pathogens that are not shared by mammalian hosts — for example, toll-like receptor (TLR)4-lipopolysaccharide, TLR5-flagellin, NOD1 and 2-peptidoglycan — all nucleic acids are made from four components that are identical from bacteria to man. Nucleoside modifications are prevalent in nature but vary greatly in their distribution and frequency, and therefore could serve as patterns for recognition of pathogenic nucleic acids. The presence of modified nucleosides in RNA reduces the activation of RNA-sensing TLRs and retinoic acid inducible gene I (RIG-I), which initiate signaling -
Current Pharmaceutical Biotechnology, 2018, 19, 611-621 REVIEW ARTICLE
Send Orders for Reprints to [email protected] 611 Current Pharmaceutical Biotechnology, 2018, 19, 611-621 REVIEW ARTICLE ISSN: 1389-2010 eISSN: 1873-4316 Current Pharmaceutical Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocel- Biotechnology Impact Factor: 1.819 The international lular Carcinoma journal for timely in-depth reviews in Pharmaceutical Biotechnology BENTHAM SCIENCE Ryan L. Setten†1,2, Helen L. Lightfoot†3, Nagy A. Habib4 and John J. Rossi1,2* 1Department of Molecular and Cellular Biology, Beckman Research Institute of City of Hope, Duarte, CA, USA; 2Irell & Manella Graduate School of Biological Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA; 3MiNA Therapeutics Limited, Translation & Innovation Hub, 80 Wood Lane, London, W12 0BZ, United Kingdom; 4Department of Surgery and Cancer, Imperial College London, London, UK Abstract: Background: Oligonucleotide drug development has revolutionised the drug discovery field. Within this field, ‘small’ or ‘short’ activating RNAs (saRNA) are a more recently discovered category of short double-stranded RNA with clinical potential. saRNAs promote transcription from target loci, a phenomenon widely observed in mammals known as RNA activation (RNAa). Objective: The ability to target a particular gene is dependent on the sequence of the saRNA. Hence, A R T I C L E H I S T O R Y the potential clinical application of saRNAs is to increase target gene expression in a sequence-specific manner. saRNA-based therapeutics present opportunities for expanding the “druggable genome” with Received: January 20, 2018 particular areas of interest including transcription factor activation and cases of haploinsufficiency. Revised: May 30, 2018 Accepted: June 01, 2018 Results and Conclusion: In this mini-review, we describe the pre-clinical development of the first DOI: saRNA drug to enter the clinic. -
Microrna in Control of Gene Expression: an Overview of Nuclear Functions
International Journal of Molecular Sciences Review MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions Caterina Catalanotto *,†, Carlo Cogoni *,† and Giuseppe Zardo *,† Department of Cellular Biotechnologies and Hematology, University of Rome Sapienza, Rome 00179, Italy * Correspondence: [email protected] (Ca.Ca.); [email protected] (Ca.Co.); [email protected] (G.Z.); Tel.: +39-064-991-8247 (G.Z.); Fax: +39-064-991-8251 (G.Z.) † These authors contributed equally to this work. Academic Editor: Y-h. Taguchi Received: 26 August 2016; Accepted: 7 October 2016; Published: 13 October 2016 Abstract: The finding that small non-coding RNAs (ncRNAs) are able to control gene expression in a sequence specific manner has had a massive impact on biology. Recent improvements in high throughput sequencing and computational prediction methods have allowed the discovery and classification of several types of ncRNAs. Based on their precursor structures, biogenesis pathways and modes of action, ncRNAs are classified as small interfering RNAs (siRNAs), microRNAs (miRNAs), PIWI-interacting RNAs (piRNAs), endogenous small interfering RNAs (endo-siRNAs or esiRNAs), promoter associate RNAs (pRNAs), small nucleolar RNAs (snoRNAs) and sno-derived RNAs. Among these, miRNAs appear as important cytoplasmic regulators of gene expression. miRNAs act as post-transcriptional regulators of their messenger RNA (mRNA) targets via mRNA degradation and/or translational repression. However, it is becoming evident that miRNAs also have specific nuclear functions. Among these, the most studied and debated activity is the miRNA-guided transcriptional control of gene expression. Although available data detail quite precisely the effectors of this activity, the mechanisms by which miRNAs identify their gene targets to control transcription are still a matter of debate. -
Nuclear Functions of Mammalian Micrornas in Gene Regulation
Liu et al. Molecular Cancer (2018) 17:64 DOI 10.1186/s12943-018-0765-5 REVIEW Open Access Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer Hongyu Liu1,2, Cheng Lei1,2, Qin He1,2, Zou Pan1,2, Desheng Xiao3 and Yongguang Tao1,2,4* Abstract MicroRNAs (miRNAs) are endogenous non-coding RNAs that contain approximately 22 nucleotides. They serve as key regulators in various biological processes and their dysregulation is implicated in many diseases including cancer and autoimmune disorders. It has been well established that the maturation of miRNAs occurs in the cytoplasm and miRNAs exert post-transcriptional gene silencing (PTGS) via RNA-induced silencing complex (RISC) pathway in the cytoplasm. However, numerous studies reaffirm the existence of mature miRNA in the nucleus, and nucleus- cytoplasm transport mechanism has also been illustrated. Moreover, active regulatory functions of nuclear miRNAs were found including PTGS, transcriptional gene silencing (TGS), and transcriptional gene activation (TGA), in which miRNAs bind nascent RNA transcripts, gene promoter regions or enhancer regions and exert further effects via epigenetic pathways. Based on existing interaction rules, some miRNA binding sites prediction software tools are developed, which are evaluated in this article. In addition, we attempt to explore and review the nuclear functions of miRNA in immunity, tumorigenesis and invasiveness of tumor. As a non-canonical aspect of miRNA action, nuclear miRNAs supplement miRNA regulatory networks and could be applied in miRNA based therapies. Keywords: microRNA, Nucleus, PTGS, TGS, TGA, Cancer, Immunity, Metastasis, Invasion MicroRNA (miRNA) is a group of small non-coding induced the expression of cold-shock domain-containing RNA that plays significant roles in multiple metabolic protein C2 (CSDC2) and E-cadherin [2].